LY 303511

08/01/2019 - "Therefore, LY303511 displays antiproliferation potential against oral cancer cells in vitro and in vivo."
08/01/2019 - "LY303511 displays antiproliferation potential against oral cancer cells in vitro and in vivo."
08/01/2019 - "Two oral cancer cells (CAL 27 and SCC-9) with highly sensitivity to LY303511 were used. "
08/01/2019 - "In MTS assay, LY303511 dose-responsively decreases survival in three kinds of oral cancer cells but little damage to normal oral cells (HGF-1). "
08/01/2019 - "In 8-oxo-2'-deoxyguanosine assay, LY303511 induces oxidative DNA damage in oral cancer cells. "

08/01/2019 - "In zebrafish model, LY303511 inhibits CAL 27-xenografted tumor growth. "
02/01/2013 - "The drug LY303511 (LY30), combined with TRAIL, caused synergistic (greater than additive) killing of multiple cancer cell lines. "
11/15/2012 - "The compound LY303511 (LY30) has been proven to induce production of ROS and to sensitize cancer cells to TRAIL-induced apoptosis, but the mechanisms and mediators of LY30-induced effects are potentially complex. "
10/01/2007 - "LY303511 amplifies TRAIL-induced apoptosis in tumor cells by enhancing DR5 oligomerization, DISC assembly, and mitochondrial permeabilization."
09/01/2005 - "In addition to its antiproliferative effect in vitro, LY303511 inhibited the growth of human prostate adenocarcinoma tumor implants in athymic mice. "

03/01/2009 - "LY303511 enhances TRAIL sensitivity of SHEP-1 neuroblastoma cells via hydrogen peroxide-mediated mitogen-activated protein kinase activation and up-regulation of death receptors."

03/04/2013 - "The effect of LY294002 and LY303511 on adenovirus-delivered transgene expression was demonstrated in 4 human lung cancer cell lines. "

04/01/2003 - "In MIN6 insulinoma cells, wortmannin (100 nM) had no effect on whole-cell outward K+ currents, but LY294002 and LY303511 reversibly blocked currents in a dose-dependent manner (IC50=9.0+/-0.7 microM and 64.6+/-9.1 microM, respectively). "